Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAP3K5 | Q99683 | 7/20 | 0.45 |
| ▸ | GRM5 | P41594 | 2/20 | 0.43 |
| ▸ | PARP1 | P09874 | 2/20 | 0.40 |
| ▸ | MYLK | Q15746 | 5/20 | 0.40 |
| ▸ | TNF | P01375 | 8/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL979098 | 0.85 | MAP3K5 (0.42) | MAP3K5MYLKTNF | |
| SCHEMBL977782 | 0.77 | MAP3K5 (0.41) | MAP3K5 | |
| SCHEMBL29949306 | 0.77 | MAP3K5 (0.49) | MAP3K5MYLKTNF | |
| SCHEMBL978873 | 0.72 | MAP3K5 (0.41) | MAP3K5MYLKTNF | |
| SCHEMBL2943452 | 0.72 | GRM5 (0.54) | GRM5PARP1 | |
| SCHEMBL17386562 | 0.71 | GRM5 (0.49) | GRM5PARP1 | |
| SCHEMBL31249984 | 0.71 | GRM5 (0.64) | GRM5PARP1 | |
| SCHEMBL29506339 | 0.71 | GRM5 (0.64) | GRM5PARP1 | |
| SCHEMBL31249988 | 0.71 | GRM5 (0.64) | GRM5PARP1 | |
| SCHEMBL997865 | 0.71 | GRM5 (0.64) | GRM5PARP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110009410-A1 | APOPTOSIS SIGNAL-REGULATING KINASE INHIBITORS | GILEAD SCIENCES, INC. (US) | 2011-01-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110009410-A1 | APOPTOSIS SIGNAL-REGULATING KINASE INHIBITORS | BAX, CASP1, AIFM1 | MAP3K5 16/4885GRM5 2399/4885PARP1 578/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.